Skip to content
ARTHEx biotech
  • About us
  • Our products
  • Pipeline
    • Publications
  • Team/Investors
  • Contact/Events
  • News

Latest Publications

Latest publications

The latest publications related to our research work, on advanced RNA treatments against genetic diseases, can be consulted online on this page.

Graphical Abstract

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy

Cerro-Herreros E, et al. Mol Ther Nucleic Acids. 2020. PMID: 32805487

DOI: https://doi.org/10.1016/j.omtn.2020.07.021

More published works will be inserted in this section in the coming days.

Arthex on Twitter

AvatarARTHEx biotech@Arthexbiotech·

November has been such an amazing month for ARTHEx! Just in case you couldn’t keep up with the good news, here’s an update from our CEO, @LlamusiBeatriz 👇🏽👇🏽
https://arthexbiotech.com/different-awards-and-grants-recognize-arthexs-efforts-to-start-up-an-innovative-treatment-for-dm1/ vía @Arthexbiotech

AvatarARTHEx biotech@Arthexbiotech·

A year ago we had the fantastic opportunity to celebrate  the
II Spanish Meeting on Oligonucleotide Therapeutics (#SMOT2). #COVID19 has made it impossible for us to repeat in 2020 but we are working on organizing an even greater edition in 2021. We will update you on #SMOT3 soon!

AvatarARTHEx biotech@Arthexbiotech·

Such good news! Keep up with the good work!💪💪

AvatarARTHEx biotech@Arthexbiotech·

The Neotec Program from the @CDTIoficial has valued us among the top 10 tech-based start-ups, and the first in #healthbiotech! With this new funding of 250k we’ll keep moving forward with the development of a drug for #DM1 patients.

2
Retweet on TwitterARTHEx biotech Retweeted
AvatarMyotonic Dystrophy Foundation@MyotonicStrong·

Mark your calendar: #GivingTuesday is Dec. 1! Join the movement and help us continue to provide invaluable resources to the DM community: https://mdf.networkforgood.com/projects/116938-2020-giving-tuesday

Load More...

News

  • Different awards and grants recognize ARTHEx’s efforts to start up an innovative treatment for DM1 November 28, 2020
  • Eric Marcusson joins ARTHEx’s  Scientific Advisory Board November 2, 2020
  • Dr Nicholas Jonhson, new Chief Medical Advisor August 28, 2020
  • Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology July 24, 2020
  • International Myotonic Dystrophy Consortium June 16, 2019

Search

Logo blanco
Drug discovery in neuromuscular diseases
ARTHEX BIOTECH. S.L
C/ Catedrático Agustín Escardino 9 – 46980 Paterna, Valencia (Spain)
Telephone: +34 625 016 629 – E-mail:  info@arthexbiotech.com
Linkedin   Facebook   Twitter
logo innvierte
logo Ministerio de Ciencia e Innovación
eit
EIT Europe
IVACE
© 2021 ARTHEx biotech • Built with GeneratePress
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read MoreACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.